PROBLEM TO BE SOLVED: To provide pharmaceutical compositions useful in treatment of S1Pmediated diseases such as respiratory diseases, fibrosis, and diseases caused by vasoconstriction.SOLUTION: Compounds represented by the general formula (I-1) have prominent portal pressure lowering effect in addition to potent human S1Pantagonistic activity, and thereby can be preventive and/or therapeutic agents for S1Pmediated diseases such as fibrosis and diseases caused by vasoconstriction.